Holen Sie sich die Stockscreener-App
0.8103
2.57%
0.0203
Handel nachbörslich:
.80
-0.0103
-1.27%
Schlusskurs vom Vortag:
$0.79
Offen:
$0.81
24-Stunden-Volumen:
87,730
Relative Volume:
0.28
Marktkapitalisierung:
$61.06M
Einnahmen:
$9.53M
Nettoeinkommen (Verlust:
$-44.61M
KGV:
-0.8904
EPS:
-0.91
Netto-Cashflow:
$-38.32M
1W Leistung:
+3.49%
1M Leistung:
+5.78%
6M Leistung:
-42.94%
1J Leistung:
+27.81%
1-Tages-Spanne:
$0.76
$0.84
1-Wochen-Bereich:
$0.76
$0.8574
52-Wochen-Spanne:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Vergleichen Sie CUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.8103 | 62.65M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
News impact scoring models applied to Cue Biopharma Inc.Weekly Gains Summary & AI Optimized Trade Strategies - Newser
Cue Biopharma Announces Initiation of Investigator Sponsored Tri - GuruFocus
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - The Manila Times
Dana-Farber Launches Trial of New Immunotherapy Drug for Aggressive Brain Cancer - Stock Titan
What technical models suggest about Cue Biopharma Inc.’s comebackWeekly Gains Report & Real-Time Market Sentiment Alerts - Newser
Cue Biopharma Inc. Facing Inflection Point in Trend Analysis2025 Buyback Activity & Weekly Top Performers Watchlists - 선데이타임즈
Order flow analysis tools used on Cue Biopharma Inc.Weekly Trade Report & Safe Capital Growth Plans - Newser
Cue Biopharma Inc. stock daily chart insights [July 2025 Recap]Consistent Profit Trade Alerts - Newser
Cue Biopharma 2025 Q2 Earnings Narrowed Losses with Modest Revenue Growth - AInvest
Can machine learning forecast Cue Biopharma Inc. recoveryFree Risk Controlled Picks With Real Returns - Newser
Advanced analytics toolkit walkthrough for Cue Biopharma Inc.Trade Exit Summary & AI Based Buy and Sell Signals - Newser
How sentiment analysis helps forecast Cue Biopharma Inc.Risk-Managed Strategy Based on Price Analysis - Newser
Short interest data insights for Cue Biopharma Inc.Free Consistent Gain Investment Strategies - Newser
Cue Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cue Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CUE BIOPHARMA Earnings Results: $CUE Reports Quarterly Earnings - Quiver Quantitative
Why Cue Biopharma Inc. stock is on top investor watchlistsSwing Reversal Forecast Based on Patterns - Newser
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights | CUE Stock News - GuruFocus
Cue Biopharma Advances Drug Development with FDA Feedback and Collaboration with Boehringer Ingelheim, Raises $20 Million in Public Offering - Quiver Quantitative
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Stock Titan
Custom Dashboard Highlights Cue Biopharma Inc. Price MomentumInvestment Strategy With Predictable Gains Outlined - 선데이타임즈
How to recover losses in Cue Biopharma Inc. stockSecure Asset Flow and Trend Pattern Analysis - Newser
How moving averages guide Cue Biopharma Inc. tradingShort-Term Market Movement Forecast Report - Newser
Earnings visualization tools for Cue Biopharma Inc.Alpha Stock Picks with Chart Confirmation - Newser
Cue Biopharma (CUE) to Release Earnings on Wednesday - Defense World
How Cue Biopharma Inc. stock performs during market volatilityCapital Protection Strategy With Risk Analysis - Newser
How to read the order book for Cue Biopharma Inc.Weekly Trend Watch with Market Signals - Newser
Is Cue Biopharma Inc. stock overvalued or fairly pricedSkyrocketing Stock Opportunities - classian.co.kr
Intraday pattern recognizer results for Cue Biopharma Inc.Free Weekly Stock Watch With Growth Focus - Newser
Published on: 2025-08-11 01:12:05 - Newser
Real time scanner hits for Cue Biopharma Inc. explainedFree Trade Setups With AI Powered Filters - Newser
Will Cue Biopharma Inc. stock benefit from interest rate changesForecasting Stock Moves with AI Insights - Newser
Will Cue Biopharma Inc. stock go up soonBuy Entry Confirmation Based on Technical Analysis - Newser
Why Cue Biopharma Inc. stock attracts strong analyst attentionSmart Trade Mapping with Entry Details - Newser
Intrinsic Value of Cue Biopharma Inc. Stock: Is It Undervalued or OvervaluedSummary of Consistent Growth Stock Picks - Newser
What makes Cue Biopharma Inc. stock price move sharplySmart Trend Analysis With Buy Point Cues - Newser
Leading vs lagging indicators on Cue Biopharma Inc. performanceFree Fundamental + Technical Hybrid Stock Tips - Newser
Should you avoid Cue Biopharma Inc. stock right nowFree Weekly Stock Watchlist - thegnnews.com
Using AI based signals to follow Cue Biopharma Inc.Free Stock Selection With High Accuracy - Newser
Multi Factor Analysis Ranks Cue Biopharma Inc. as Strong BuySecure Capital Picks With Upside Potential Tracked - beatles.ru
Cue Biopharma Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
How to integrate Cue Biopharma Inc. into portfolio analysis toolsFree Entry Points For Growing Stocks - Newser
Cue Biopharma Inc. stock trend outlook and recovery pathSafe Entry Screening with Data Backed Analysis - Newser
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):